SEARCH:
Print

MVA-BN HIV

Human Immunodeficiency Virus (HIV-1) vaccine candidate

PRECLINICAL


MVA-BN HIV is a new vaccine candidate, designed for Janssen as part of the development of a prime-boost vaccine regimen with Janssen’s AdVac technology.

Significant progress has been made in the global battle against HIV/AIDS, including the development of critical antiretroviral treatments and HIV prevention tools, yet the disease remains one of the greatest global health threats of our time. An estimated 37 million people are currently living with HIV-1 globally, and nearly 2 million people become newly infected each year.